111 related articles for article (PubMed ID: 20693274)
1. Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study.
Olofsson T; Englund M; Saxne T; Jöud A; Jacobsson LT; Geborek P; Allaire S; Petersson IF
Ann Rheum Dis; 2010 Dec; 69(12):2131-6. PubMed ID: 20693274
[TBL] [Abstract][Full Text] [Related]
2. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
[TBL] [Abstract][Full Text] [Related]
3. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice.
Neovius M; Simard JF; Klareskog L; Askling J;
Ann Rheum Dis; 2011 Aug; 70(8):1407-14. PubMed ID: 21518724
[TBL] [Abstract][Full Text] [Related]
4. Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.
Kristensen LE; Petersson IF; Geborek P; Jöud A; Saxne T; Jacobsson LT; Englund M
Rheumatology (Oxford); 2012 Feb; 51(2):243-9. PubMed ID: 21565900
[TBL] [Abstract][Full Text] [Related]
5. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF
Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
[TBL] [Abstract][Full Text] [Related]
6. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
[TBL] [Abstract][Full Text] [Related]
7. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?
Olofsson T; Petersson IF; Eriksson JK; Englund M; Nilsson JA; Geborek P; Jacobsson LTH; Askling J; Neovius M;
Ann Rheum Dis; 2017 Jul; 76(7):1245-1252. PubMed ID: 28073801
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
[TBL] [Abstract][Full Text] [Related]
9. Does disease activity at start of biologic therapy influence work-loss in RA patients?
Olofsson T; Johansson K; Eriksson JK; van Vollenhoven R; Miller H; Petersson IF; Askling J; Neovius M
Rheumatology (Oxford); 2016 Apr; 55(4):729-34. PubMed ID: 26683196
[TBL] [Abstract][Full Text] [Related]
10. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative Arthritis Centres.
Ziegler S; Huscher D; Karberg K; Krause A; Wassenberg S; Zink A
Ann Rheum Dis; 2010 Oct; 69(10):1803-8. PubMed ID: 20447953
[TBL] [Abstract][Full Text] [Related]
11. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.
Raaschou P; Simard JF; Holmqvist M; Askling J;
BMJ; 2013 Apr; 346():f1939. PubMed ID: 23568792
[TBL] [Abstract][Full Text] [Related]
13. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
[TBL] [Abstract][Full Text] [Related]
15. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Nilsson JA; Petersson IF; Lindqvist E; Saxne T; Geborek P
Ann Rheum Dis; 2007 May; 66(5):670-5. PubMed ID: 17158824
[TBL] [Abstract][Full Text] [Related]
16. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden.
Söderlin MK; Lindroth Y; Jacobsson LT
Rheumatology (Oxford); 2007 Aug; 46(8):1355-8. PubMed ID: 17567634
[TBL] [Abstract][Full Text] [Related]
17. Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden.
Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1399-406. PubMed ID: 20506121
[TBL] [Abstract][Full Text] [Related]
18. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.
Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
Ann Rheum Dis; 2010 Feb; 69(2):352-7. PubMed ID: 19282310
[TBL] [Abstract][Full Text] [Related]
19. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis.
Listing J; Brandt J; Rudwaleit M; Zink A; Sieper J; Braun J
Ann Rheum Dis; 2004 Dec; 63(12):1670-2. PubMed ID: 15547093
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for disability pension in a population-based cohort of men and women on long-term sick leave in Sweden.
Karlsson NE; Carstensen JM; Gjesdal S; Alexanderson KA
Eur J Public Health; 2008 Jun; 18(3):224-31. PubMed ID: 18245150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
